Opaleye Management Inc. Lumos Pharma, Inc. Transaction History

Opaleye Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.35 - $9.05 $184,161 - $226,756	25,056 Added 116.43%	46,576 $412,000
Q2 2022 Aug 15, 2022	BUY	$6.68 - $9.39 $143,753 - $202,072	21,520 New	21,520 $166,000
Q3 2021 Nov 16, 2021	SELL	$7.36 - $11.36 $2.81 Million - $4.34 Million	-382,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.75 - $13.44 $49,725 - $68,544	5,100 Added 1.35%	382,000 $3.82 Million
Q1 2021 May 18, 2021	BUY	$11.58 - $31.11 $1.11 Million - $2.97 Million	95,613 Added 33.99%	376,900 $4.41 Million
Q4 2020 Feb 12, 2021	BUY	$13.61 - $35.91 $549,775 - $1.45 Million	40,395 Added 16.77%	281,287 $10 Million
Q3 2020 Nov 16, 2020	BUY	$13.25 - $16.5 $3.19 Million - $3.97 Million	240,892 New	240,892 $3.33 Million

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.